The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers.
Anna BalatoAlexander ZinkGraziella BabinoDario BuononatoCharlotte KianiKilian EyerichStefanie ZiehfreundEmanuele ScalaPublished in: Life (Basel, Switzerland) (2022)
Psoriasis (PSO) and Atopic dermatitis (AD) are common inflammatory skin diseases that affect people of all ages globally. They negatively impact the quality of life (QoL) of patients in health-related aspects such as physical, psychological and mental functioning. Here, we conducted a review of studies relating to candidate biomarkers and indicators associated with QoL impairment in PSO and AD. Data research was performed using PUBMED and SCOPUS databases from inception to September 2022. Most of the included studies reported genomic or proteomic biomarkers associated with disease activity and QoL outcomes. Sociodemographic, clinical and therapeutic factors have also been implicated in deterioration of life quality in these patients. The inclusion of clinical characteristics, QoL impairment and co-diagnosis should be considered in drug development programs, since processing biomarkers based on an increased number of features in addition to drug class and disease will intensify the value of the biomarker itself, thereby maximizing the future clinical utility as a stratification tool.
Keyphrases
- atopic dermatitis
- end stage renal disease
- disease activity
- ejection fraction
- newly diagnosed
- rheumatoid arthritis
- chronic kidney disease
- systemic lupus erythematosus
- mental health
- peritoneal dialysis
- systematic review
- physical activity
- type diabetes
- emergency department
- public health
- prognostic factors
- metabolic syndrome
- gene expression
- machine learning
- electronic health record
- rheumatoid arthritis patients
- sleep quality
- adverse drug
- insulin resistance
- soft tissue
- juvenile idiopathic arthritis
- drug induced
- genome wide